Results 51 to 60 of about 136,291 (302)
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Rapid solubility and mineral storage of CO2 in basalt [PDF]
, 2014 The long-term security of geologic carbon storage is critical to its success and public acceptance. Much of the security risk associated with geological carbon storage stems from its buoyancy.
Gislason S.R et al
core +1 more source
Разработка и регистрация лекарственных средств, 2020 Introduction. An innovative pharmaceutical substance based on the 3,7-diazabicyclo[3.3.1]nonane derivative provides long-term activation of AMPA receptors and the production of neurotrophic factors, which makes it possible to use it for the treatment of ...
G. E. Brkich +5 more
doaj +1 more source
Molecular Oncology, EarlyView.CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak +10 more
wiley +1 more source
From microstructures of tablets and granules to their dissolution behaviour
, 2006 Dissolution testing is now an established and standardised method for measuring the performance of drug products. It allows results for different batches of the same product, similar products from different suppliers,or tests from different labs to be ...
Jia, Xiaodong, Williams, Richard A
core +1 more source
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
An inferential procedure for the probability of passing the USP dissolution test
, 2022 Dissolution is one of the tests that is required and specified by the United States Pharmacopeia and National Formulary (USP/NF) to ensure that the drug products meet the standards of the identity, strength, quality, purity, and stability.
Chiang, Chieh;Chen, Chen‐Fang;Huang, Meng‐Yang;Liu, Jen‐Pei
core +2 more sources
Challenges in Dissolution Testing
Dissolution Technologies, 2012 Dissolution testing of dosage forms is an activity in continuous development, both for improving equipment and its performance qualification and for selecting the best test conditions. The U. S. Pharmacopeia (USP) held a workshop coordinated by some USP expert panels at its headquarters in Rockville, MD, on June 11 and 12, 2012, to present and discuss ...
Margareth R. C. Marques +7 more
openaire +1 more source
Dissolution testing of orally disintegrating tablets
Journal of Pharmacy and Pharmacology, 2012 Abstract For industrially manufactured pharmaceutical dosage forms, product quality tests and performance tests are required to ascertain the quality of the final product. Current compendial requirements specify a disintegration and/or a dissolution test to check the quality of oral solid dosage forms.
Johannes, Kraemer +4 more
openaire +2 more sources